Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.

Janez A, Őrsy P, Stachlewska K, Salvesen-Sykes K, Billings LK, Philis-Tsimikas A

Diabetes, obesity & metabolism27 Jan 2020Cited by 3 (Europe PMC)

PMID31858673PMCIDPMC7079143DOI10.1111/dom.13944PepBankPUB-31858673

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the fixed-dose combination IDegLira was favourable versus insulin comparators for HbA1c change, regardless of pretrial sulphonylurea or DPP-4 inhibitor use.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination was better than insulin alone for HbA1c, whether or not people used earlier tablets.
Peptide
Liraglutide
Outcome
Direction not reportedHbA1c change by pretrial SU/DPP4i use
Study
n: not reported in source
Comparator
Insulin degludec (DUAL II) or insulin glargine U100 (DUAL IX)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Regardless of pretrial SU/DPP4i use, IDegLira was favourable versus insulin comparators with respect to change in HbA1c and body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U).
Summary · context
In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add-on to sodium-glucose co-transporter-2 inhibitors ± oral antidiabetic drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3185867301
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the fixed-dose combination IDegLira was favourable versus insulin comparators for body weight change, regardless of pretrial sulphonylurea or DPP-4 inhibitor use.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination was better than insulin alone for body weight, whether or not people used earlier tablets.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight change by pretrial SU/DPP4i use
Study
n: not reported in source
Comparator
Insulin degludec (DUAL II) or insulin glargine U100 (DUAL IX)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Regardless of pretrial SU/DPP4i use, IDegLira was favourable versus insulin comparators with respect to change in HbA1c and body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U).
Summary · context
In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add-on to sodium-glucose co-transporter-2 inhibitors ± oral antidiabetic drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3185867302
03HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, the fixed-dose combination IDegLira gave lower hypoglycaemia rates than insulin comparators, regardless of pretrial regimen.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination caused less low blood sugar than insulin alone, whatever people used before.
Peptide
Liraglutide
Outcome
DecreaseHypoglycaemia rate
Study
n: not reported in source
Comparator
Insulin degludec (DUAL II) or insulin glargine U100 (DUAL IX)
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Lower hypoglycaemia rates and comparable end-of-trial daily insulin dose were achieved with IDegLira, regardless of pretrial regimen.
2 context sentences(design, population, supporting numbers)
Summary · context
In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U).
Summary · context
In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add-on to sodium-glucose co-transporter-2 inhibitors ± oral antidiabetic drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3185867303
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the end-of-trial daily insulin dose was comparable between the fixed-dose combination IDegLira and insulin comparators, regardless of pretrial regimen.
In plain wordsIn adults with type 2 diabetes, the final daily insulin dose was similar on the insulin degludec/liraglutide combination and on insulin alone.
Peptide
Liraglutide
Outcome
No significant changeEnd-of-trial daily insulin dose
Study
n: not reported in source
Comparator
Insulin degludec (DUAL II) or insulin glargine U100 (DUAL IX)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Lower hypoglycaemia rates and comparable end-of-trial daily insulin dose were achieved with IDegLira, regardless of pretrial regimen.
2 context sentences(design, population, supporting numbers)
Summary · context
In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U).
Summary · context
In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add-on to sodium-glucose co-transporter-2 inhibitors ± oral antidiabetic drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3185867304
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, there was no clinically relevant increase in mean self-measured blood glucose in the early weeks after starting the fixed-dose combination IDegLira.
In plain wordsIn adults with type 2 diabetes, starting the insulin degludec/liraglutide combination did not clearly raise average blood sugar in the first weeks.
Peptide
Liraglutide
Outcome
No significant changeMean self-measured blood glucose in early weeks
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was no clinically relevant increase in mean self-measured blood glucose in the early weeks after IDegLira initiation.
2 context sentences(design, population, supporting numbers)
Summary · context
In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U).
Summary · context
In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add-on to sodium-glucose co-transporter-2 inhibitors ± oral antidiabetic drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3185867305
06HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes, there was no statistically significant interaction between the randomized treatments and previous sulphonylurea or DPP-4 inhibitor use.
In plain wordsIn adults with type 2 diabetes, earlier use of sulphonylureas or DPP-4 inhibitors did not change how the treatments compared.
Peptide
Liraglutide
Outcome
No significant changeInteraction between randomized treatment and previous SU/DPP4i use
Study
n: not reported in source
Comparator
Insulin degludec (DUAL II) or insulin glargine U100 (DUAL IX)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was no statistically significant interaction between the randomized treatments and previous SU/DPP4i use.
2 context sentences(design, population, supporting numbers)
Summary · context
In DUAL II, patients with T2D uncontrolled on basal insulin and metformin ± SU/glinides were randomized to insulin degludec or IDegLira (both capped at 50 U).
Summary · context
In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add-on to sodium-glucose co-transporter-2 inhibitors ± oral antidiabetic drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3185867306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.